Summary
This prediction ended on 14.03.14 with a price of €20.20. The price of Arcam AB has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -23.81%. gerihouse has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arcam AB | - | - | - | - |
| iShares Core DAX® | -1,06 % | 5,01 % | 6,60 % | 64,71 % |
| iShares Nasdaq 100 | -2,39 % | 0,86 % | 25,79 % | 88,24 % |
| iShares Nikkei 225® | -4,36 % | 1,21 % | 41,31 % | 79,31 % |
| iShares S&P 500 | -1,78 % | 1,39 % | 21,04 % | 69,60 % |
Comments by gerihouse for this prediction
In the thread Arcam AB diskutieren
Gut im Geschäft
Nach letzten Rücksetzer wird Arcam weiter steigen.
Auszüge aus dem Jahresreport 2013:
Strategic initiatives and substantially increased sales
- Net sales increased by 43% to 199.4 (139.1) MSEK Profit after financial items increased to 15.4 (15.0) MSEK (including non-recurring costs of 5 MSEK)
- Earnings per share amounted to 3.85 (4.04) SEK (based on the number of shares before split 4:1 in January 2014)
- 25 (15) EBM systems were delivered during the period
- Order intake amounted to 27 (24) systems, and the order book contained 12 (10) systems by year-end
- 450 MSEK raised through new share issues
- Strategic alliance with DiSanto Technology, USA
- Agreement for acquisition of metal powder manufacturer AP&C, Canada
Whereof for the fourth quarter:
- Sales increased to 66.9 (62.5) MSEK
- Profit after financial items amounted to 7.6 (13.7) MSEK
- Order intake amounted to 10 (12) systems
- 9 (8) EBM systems were delivered in the fourth quarter
Significant events after the end of 2013:
- Split of shares 4:1
- Order from aerospace industry in the US
- Order from a Chinese implant manufacturer
- Order from New Zealand
(Vom Mitglied beendet)